Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)

Trial Profile

Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Losartan (Primary)
  • Indications Atrial fibrillation
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 04 Jan 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 21 Nov 2011 Planned End Date changed from 1 Dec 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 21 Nov 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top